Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + Trametinib in Pediatric Refractory/Recurrent LCH
NCT06902792Phase 1Enrolling by invitation
- Sponsor
- The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University
- Start
- Feb 2025
- Primary completion
- Aug 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of adebrelimab in Langerhans cell histiocytosis (LCH), sponsored by The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University. Primary endpoint: Disease Activity Score at 3 years. Started Feb 2025; status: enrolling by invitation.
02
Drugs
adebrelimab
03
Conditions
Langerhans cell histiocytosis (LCH)
Beyond the preview
Go deeper on NCT06902792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06902792.